The incidence of HDFN due to RhD has fallen substantially since the introduction of RhD immunoglobulin. However, the identification of a pregnant woman at risk of RhD senstitisation is extremely important to ensure that she receives RhD immunoglobulin appropriately.

Here, Dr Helen Savoia talks about HDFN, sensitising events and the management of RhD negative women with regard to laboratory testing, surveillance and administration of RhD immunoglobulin in line with the 'Prophylactic use of RhD immunoglobulin in pregnancy care' guideline available at www.blood.gov.au.